700 patients to reveal how new arthritis drugs perform in the real world
NCT ID NCT07166315
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will follow 700 adults with axial spondyloarthritis or psoriatic arthritis who have recently started one of several newer treatments (bimekizumab, upadacitinib, risankizumab, guselkumab, or a TNF inhibitor). Researchers will collect medical records and patient surveys to see how well these treatments control disease activity and improve quality of life over 12 months. The goal is to understand real-world effectiveness from both doctor and patient perspectives.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If this study succeeds, it could help doctors understand which treatments work best for these conditions in everyday practice.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by factors like patient selection or incomplete data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS (PSA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Royal National Hospital for Rheumatic Diseases
RECRUITINGBath, Somerset, BA1 3NG, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact